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Abstract
Background: Pancreatic adenocarcinoma (PDAC) incidence is increasing worldwide. Several studies have shown that
lymphopenia was correlated with a poor prognosis but the potential interest to measure lymphopenia in the pre and
post-operative setting as well as its added value among conventional prognostic factors was never investigated.
Methods: Data from two independent cohorts in whom patients underwent resection for pancreatic carcinoma
were retrospectively recorded. We examined the association between perioperative findings, pre and post-operative
lymphocyte counts and overall survival (OS) in univariate and multivariate analyses. Performance assessment
and internal validation of the final model were evaluated with Harrell’s C-index, calibration plot and bootstrap
sample procedures.
Results: Three hundred ninety patients were included in the analysis between 2000 and 2011. Pre and post-operative
lymphocyte counts were independent prognostic factors associated with OS in multivariate analysis (p = 0.0128 and
p = 0.0764, respectively). The addition of lymphocyte count variable to the conventional parameters identified in
multivariate analysis (metastatic lymph node ratio, veinous emboli and adjuvant chemotherapy) significantly improved
the model discrimination capacity (bootstrap mean difference = 0.04; 95 % CI, 0.01–0.06). The use of a threshold and
combining the categorical (≥1000; <1000) information in pre and post lymphocyte counts permitted the identification
of 4 subgroups of patients with different prognosis (p < 0.0001). Finally, the description of patients in long-term
remission showed that only 3 of 65 (4.6 %) patients with post-operative lymphocyte count under 1000/mm3 were alive
4 years after surgery contrary to 54 of 236 (22.8 %) patients with a post-operative lymphocyte count above 1000/mm3.
Conclusion: Pre and post-operative lymphopenia are independent prognostic factors for OS and they have an
additive value regarding conventional prognostic factors for death-risk stratification and to predict long-term
survival. Lymphopenia should be included as stratification factors in future clinical trial assessing overall survival
in pancreatic cancer patients.
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Background
Pancreatic ductal adenocarcinoma incidence and mortal-
ity is increasing worldwide and is one of the leading
causes of cancer-related death [1–3]. Surgical pancreatic
resection is the only curative treatment. However, patients
treated by surgery and adjuvant chemotherapy only
achieved 10–20 % of long-term survival [4, 5]. Then,
the identification of prognostic factors correlated with
the risk of early relapse is an important issue to better
optimize neoadjuvant or adjuvant treatments.
Current recognized prognostic factors include mainly
pathological parameters such as lymph node invasion,
tumour grade and resection margin involvement [6]. How-
ever, these conventional clinical parameters as well as gene
mutation status are insufficient to predict accurately death-
risk and the probability of long-term remission [7, 8].
A growing body of evidence suggests that immune-
related biomarkers are correlated with survival in several
cancers. A high infiltration of tumours by CD8+ T cell
lymphocytes (TILs) was correlated to a good prognosis
in colorectal and pancreatic cancers [9–11]. Conversely,
cancers endowed with the ability to escape the immune
system are expected to display a worse prognosis. In-
flammation, recruitment of suppressive immune cells
(regulatory T lymphocytes or myeloid derived suppres-
sor cells) or induction of lymphocyte-apoptosis mediated
by tumour cells, are potential mechanisms leading to
immune escape [12]. Peripheral blood lymphocyte count
to assess lymphopenia in cancer patients might be a con-
venient and clinically relevant option to identify cancers
associated with an enhanced risk of tumour immune
evasion and poor prognosis.
Several studies have shown that an elevated preopera-
tive neutrophil-to-lymphocyte ratio and a decreased
preoperative lymphocyte count allow the prediction of
chemotherapy-related toxicities [13, 14]. Moreover, pre-
operative lymphopenia might be a prognostic factor for
several cancer patients [15–17]. In pancreatic cancer,
immune suppression at baseline is also correlated with
overall survival. However, despite the number of studies
conducted so far, lymphocyte count parameter is not
used in current practice, probably because its additive
value regarding conventional prognostic markers is still
not widely known [18–22]. Furthermore, recent ad-
vances in immunology evidenced that chemotherapy
might promote an immunogenic cell death leading to an
increased anti-tumour immunity [23]. The presence of a
lymphopenia after surgery might impact the efficacy of
adjuvant chemotherapy. Having observed in current
clinical practice that most patients with pre-operative
lymphopenia have a lymphocyte count above 1000/mm3
1-month post surgery, we hypothesized that the prog-
nostic value of lymphopenia might be more accurate
when assessed after pancreatic adenocarcinoma removal.
Consequently, we decided to conduct a study based on
two independent cohorts including 390 patients treated
by surgery for a localized pancreatic adenocarcinoma.
The aims of this study were: i) to conduct a confirmatory
study to validate the prognosis value of pre-operative
lymphopenia, ii) to assess the impact of post-operative
lymphopenia on overall survival, iii) to discriminate the
additive value of pre and post-operative lymphocyte
counts among conventional prognosis factors.
Methods
Population
This retrospective analysis included data from two in-
dependent cohorts of patients with histologically con-
firmed pancreatic adenocarcinoma, who underwent a
curative intent surgery. The first cohort included patients
treated in a university hospital (Georges Pompidou
European Hospital, henceforth referred as HEGP) and
in a regional cancer institute (university hospital of
Besançon, Belfort and Montbeliard general hospital)
between January 1, 2000 and April 30, 2010. The sec-
ond cohort included patients treated in the university
hospital of Strasbourg (Hautepierre) between January 1,
2004 and December 31, 2011. We excluded patients
with other histopathological type of cancers: cholangio-
carcinoma, neuroendocrine tumor and patients for
whom preoperative lymphocyte count parameter was
not available. Data from the two cohorts were updated
in june, 2013.
Data collection
The following data were collected at diagnosis for each
patient: center and patient identification, age, sex,
diabetes, level of albuminemia which is the presence of
albumin in blood, pathological characteristics and
prescription of adjuvant chemotherapy. Lymphocyte
counts on routine blood tests were recorded the day
before the surgery and 1 month after the surgery.
Deaths were collected during the follow-up of the study
for each patients. All data from the two cohorts were
extracted from the paper files and the desktop folder
for each patient. The software was ChimioProd and
Dxcare, Millenium, Axigate and Dxcare for HEGP, Belfort
and Montbeliard, Besançon and Strasbourg Hospitals
respectively. Adjuvant chemotherapy data from Belfort,
Montbeliard and Besançon hospitals were excerpted
from a regional register (BPC software).
Statistical analysis
We provided the mean (SD) values and frequency (per-
centages) for the description of continuous and categorical
variables, respectively. The means and the proportion
were compared using Student’s t test and the chi-squared
test (or Fisher’s exact test, if appropriate), respectively.
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Due to the skewed lymphocyte count distribution we
used for its description the median, and the interquar-
tile range for the dispersion measurement, as recom-
mended [24]. Wilcoxon rank-sum test was performed
for lymphocyte count distribution comparison among
the cohort set.
Overall Survival (OS) was calculated from the date of
surgery to the date of death from any cause. Alive
patients were censored at the last follow-up. OS was
estimated using Kaplan Meier method and described
using median or rate at specific time points with 95 %
confidence intervals (CI). Follow-up was calculated
using reverse Kaplan-Meier estimation.
The association of parameters at enrolment with OS
was assessed using univariate Cox to produce the hazard
ratio (HR) and 95 % confidence intervals firstly for pre-
operative parameters, tumoral, therapeutic and lympho-
cyte count factors. Separate multivariate cox-analysis in
conventional factors block (pre-operative, tumoral and
therapeutic) and lymphocyte count block were per-
formed with stepwise backward – elimination with the
inclusion of variable with p < 0.05 in univariate analysis.
The factors identified in these analyses were thereafter
included in a final multivariate model with stepwise
backward – elimination. When used in continuous in
the Cox modelisation, lymphocyte count variable had to
be normalized by logarithmic transformation, consider-
ing its skewed distribution. The lymph node ratio was
defined by the ratio of the number of involved lymph
nodes reported to the total number of lymph nodes re-
moved in the lymph node dissection. The threshold 0.2
was kept as proposed in the study of Yamamoto et al.
[25]. Hazard proportionality was checked by plotting
log-minus-log survival curves.
Accuracy of the final model was checked regarding
two parameters: discrimination and calibration. The pre-
dictive value and the discrimination ability of the model
were evaluated with Harrell’s Concordance (C)-index.
One thousand random samples of the population were
used to derive 95 % CI for the Harrell’s Concordance
statistic. Calibration and goodness of fit of the model
were assessed by using the extension of Hosmer-
Lemeshow test and for survival analysis and p-value
greater than 0.1 was considered as an indicator for
acceptable agreement. Calibration was also assessed by
visual examination of calibration plot. Internal validity
of the model was assessed by a bootstrap sample
procedure. Several approaches have been proposed to
assess the performance in samples of the same popula-
tion (internal validation). Sensitivity analyses were per-
formed for univariate and multivariate Cox models with
a stratified approach on the cohort set parameter that
allowed considering the two cohort heterogeneities in
the Cox modelisation.
The predictive value that lymphocytes counts variables
added to a reference risk model (all parameters identified
in the multivariate final model except lymphocytes counts
variables) was evaluated with the use of C-statistic. This
analysis was repeated 1000 times using bootstrap samples
to derive 95 % CI for the difference in the C-statistics
between the two models in order to finally, assess the
improvement in discrimination of lymphocytes counts
parameters among the other conventional parameters.
We also used net continuous reclassification improve-
ment (NRI) and integrated discrimination improvement
(IDI) to quantify the performance and the net benefit of
the addition of lymphocyte count to the reference model
for the prediction of 48 months death probability. Con-
tinuous NRI has several limitations but would give a
consistent message and is therefore a descriptive marker.
One should note, cNRI does not consider the magnitude
of the change, but only the direction. This is done by the
IDI. When significantly greater than 0, IDI and cNRI are
in favour of a net benefit of the addition of the marker
of interest to the reference model considered.
Then, we investigated the possibility to provide a simple
implementation of lymphocyte count parameter in clinical
practice, guided by the determination for a relevant cut-
off in order to categorize patients at baseline and post-
operative time. According to the study of Ray-Coquard
and al the threshold chosen was 1000 cells/mm3 [26]. In
addition, in clinical current practice considerations,
patients with a lymphocyte count lower than 1000 are
commonly considered in a lymphopenic status.
Finally, considering the added value of lymphocyte
count measurements for OS risk stratification among con-
ventional factors and their independent association with
OS, we investigated the interest for a combination of pre
and post-operative lymphocyte count in clinical practice.
The analyses were conducted using SAS 9.2 (Statistical
Analysis System, Cary, NC, USA) and R 3.0.2 (R founda-
tion for Statistical Computing). All statistical tests were




Characteristics of the overall population and according
to the two cohort sets are given in Table 1. A total of
390 patients with resectable pancreatic cancers were en-
rolled. There were 192 (49,2 %) patients in cohort 1 and
198 (50,8 %) in cohort 2. Pathological findings differed
significantly between the two cohorts but the most fre-
quent T stage was T3-T4 in both cohorts (85 and 94 %
respectively in cohort 1 and 2; p < 0.01). However OS of
the patients in the two cohorts were not significantly
different (Additional file 1: Figure S1, HR = 0.870 95 %
CI: 0.696–1.088 p = 0.2235).
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Table 1 Baseline characteristics of the overall population and according to the two cohort sets








Pre-operative parameters Age at surgery — years 390 192 198
≤ 65 174 (45 %) 87 (45 %) 87 (44 %)
> 65 216 (55 %) 105 (55 %) 111 (56 %) 0.8387
Patient male sex— no. (%) 390 222 (57 %) 192 103 (54 %) 198 119 (60 %) 0.2201
Diabetes— no. (%) 325 186 139
No 252 (78 %) 143 (77 %) 109 (78 %)
Yes 73 (22 %) 43 (23 %) 30 (22 %) 0.7891
Albuminemia g/L 191 36.4 ± 7.7 70 32.6 ± 6.4 121 38.6 ± 7.4 <0.0001
Tumor Size in cm 301 3.8 ± 1.6 164 3.6 ± 1.5 137 4.0 ± 1.6 0.0095
Tumoral post-operative
parameters
pT Local invasion— no. (%) 375 184 193
0-1-2 39 (10 %) 28 (15 %) 11 (6 %)
3–4 336 (90 %) 154 (85 %) 182 (94 %) 0.0022
N status 388 190 198
0 119 (31 %) 68 (36 %) 51 (26 %)
1 269 (69 %) 122 (64 %) 147 (74 %) 0.0365
Positive lymph nodes ratio 380 0.15 ± 0.19 182 0.20 ± 0.23 198 0.12 ± 0.14 <0.0001
Lymph Nodes ratio
< 0.2 380 279 (73 %) 117 (64 %) 162 (81 %)
≥ 0.2 104 (27 %) 67 (36 %) 37 (19 %) <0.0001
Histological Grade 331 160 171
Poorly differentiated 85 (26 %) 23 (14 %) 62 (36 %)
Moderately differentiated 158 (48 %) 76 (48 %) 82 (48 %)
Well differentiated 88 (26 %) 61 (38 %) 27 (16 %) <0.0001
Vascular invasion 361 186 175
No 242 (67 %) 115 (62 %) 127 (73 %)
Yes 119 (33 %) 71 (38 %) 48 (27 %) 0.0335
Lymphatic invasion 364 189 175
No 230 (63 %) 107 (57 %) 123 (70 %)
Yes 134 (37 %) 82 (43 %) 52 (30 %) 0.0089
Perineural invasion 365 191 174
No 138 (38 %) 57 (30 %) 81 (47 %)
Yes 227 (62 %) 134 (70 %) 93 (53 %) 0.0012
Therapeutic
post-operative parameter
Adjuvant Chemotherapy 336 251 (75 %) 183 118 (64 %) 153 133 (87 %) <0.0001
Lymphopenia parameters Pre-operative
lymphocyte counta
390 1458.9 (150–8350) 194 1492.1 (170–3052) 199 1426 (150–8350) 0.3362
Post-operative
lymphocyte counta
299 1410 (200–32000) 127 1400 (251–3620) 172 1430 (200–32000) 0.2657
Follow-up parameters Death events 393 309 (79 %) 192 157 (82 %) 198 152 (77 %) 0.2233
Median F-up time in
months 95 % CIb
66.6 (60.8–78.7) 66.6 (58.0–84.0) 67.2 (56.2–79.0)
Abbreviations: pT histologic tumoral invasion, Nstatus lymph node status, F-up follow-up, lymph node ratio (Number of positive lymph nodes/Total number of lymph nodes)
amedian (min-max) were reported for lymphocyte count due to their skewed distribution
bCI denotes confidence interval
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Independent prognostic factors of OS
The association of pre-operative, tumoral and therapeutic
post-operative factors, as well as lymphocyte counts
with OS in univariate analysis is shown in Table 2. We
identified 9 variables as prognostic factors for OS in the
univariate analysis: age at surgery (p = 0.003), serum al-
bumin (p = 0.009), lymph nodes ratio ≥ 0.2 (p < 0.0001),
histological grade (p = 0.007), venous emboli (VE) (p =
0.004), adjuvant chemotherapy (ACT) (p < 0.0001), pre
and post-operative lymphocyte counts (p = 0.0023 and
p = 0.0065 respectively).
Separate multivariate cox-analysis in conventional
factors block (pre-operative, tumoral and therapeutic
post-operative) identified three factors independently
associated with OS: lymph nodes ratio (HR = 1.8, 95 % CI:
1.286–2.438, p = 0.001), venous emboli (HR = 1.5 95 % CI:
1.126–2.042, p = 0.007), and adjuvant chemotherapy (HR =
0.4, 95 % CI: 0.276–0.550, p < 0.0001) (Additional file 2:
Table S1A). Similarly, a separate multivariate cox-analysis
in lymphocyte count parameters identified pre and post-
operative lymphocyte counts as factors independently
associated with OS (Additional file 2: Table S1B; p = 0.02
and p = 0.0467 respectively). Factors identified in these
two previous multivariate analyses were thereafter in-
cluded in a final multivariate model presented in Table 3.
The final multivariate model exhibited four parameters
significantly independently associated with OS with a p
value <0.05 and one parameter borderline probably due to
a lack of power: lymph nodes ratio (p = 0.0001), venous
emboli (p = 0.0114), adjuvant chemotherapy (p = 0.0014),
pre and post-operative lymphocyte counts (p = 0.0128 and
p = 0.0764 respectively). When considered as continuous
pre and post-operative lymphocyte count variables, their
non-parametric Spearman correlation coefficient is equal
to 0.36446 (p-value < 0.0001). Then, there is a moderate
correlation between the two parameters allowing their
consideration in the final multivariate model development.
Final multivariate model performance assessment
Accuracy of the model was checked regarding two pa-
rameters: discrimination and calibration, which measure
the ability to separate patients with different prognosis
and to provide unbiased survival predictions in groups
of similar patients, respectively. Our final multivariable
Cox model exhibited good calibration as shown in the
calibration plot (Additional file 3: Figure S2) and accept-
able discrimination (C-statistic 0.64; 95 % CI: 0.60–0.69).
With the replicated datasets (n = 1000) derived from
the bootstrap sample procedure, uncertainties around
hazard ratio estimates can be measured. Bootstrapping
results for the internal validation reflect the robustness of
the final model as presented in Table 3. A sensitivity ana-
lysis was performed to validate the robustness of our final
model with a stratified approach. By forcing prognostic
factors not involved in the multivariate analysis (T, N and
age) results remained similar reflecting the robustness of
our final model (Additional file 4: Table S2).
Additional value of pre and post-operative lymphocyte
count parameters for OS prediction
The inclusion of pre and post-operative lymphocyte
count parameters in the reference model (including only
conventional parameters) was found to significantly im-
prove the discriminative ability of the model, because
the C statistic increased significantly from 0.60–0.64
(bootstrap mean difference = 0.04; 95 % CI, 0.01–0.06).
These results show that the addition of lymphocyte
count parameter to clinical conventional parameters im-
proved the stratification of patients at risk for death and
then the model discrimination capacity. Similarly, the
addition of lymphocyte count block to the conventional
parameter block adequately reclassified at 48 months pa-
tients at lower risk for death and those at higher risk, as
shown by a continuous net reclassification improvement
of 0.3355 (95 % CI, 0.0719–0.5991; p = 0.01261; Fig. 1)
and the integrated discrimination improvement was 0.03
(95 % CI, 0.01–0.06; p = 0.00339).
Medians (minimal-maximal) of pre and post-operative
lymphocyte counts in our population were 1320 (150–
8350) and 1410 (200–32000), respectively. Thus, the
total lymphocyte count was categorized using a thresh-
old of 1000 cells/mm3. Among the 390 patients involved
in the final analysis, 110 (28 %) had lymphocyte count
below 1000/mm3 at baseline and exhibited different
prognostic profiles for OS (p = 0.0028). Post-operative
lymphocyte count parameter was available for 301 pa-
tients. 65 (22 %) of them had post-operative lymphope-
nia. A pejorative correlation with OS was also evidenced
(Table 2, Fig. 2a and b, p < 0.0001).
By combining the categorical (>1000; ≤1000) informa-
tion in pre and post-operative lymphocyte counts we
identified 4 groups of patients with different prognostic
profiles. Within patient’s pre and post-operative data
available, 219 had a baseline lymphocyte count above
1000/mm3. 37 (17 %) of them were classified as lympho-
penic 1 month after surgery and had poor prognosis
(HR = 2.2; 95 % CI: 1.476–3.317 p < 0.0001). In addition,
among the 83 patients of this cohort who displayed
pre-operative lymphopenia, 55 (66 %) normalized their
lymphocyte count after surgery and had a better prog-
nosis (HR = 1.5; 95 % CI: 1.058; 2.088 p < 0.0001). Pa-
tients with the worst outcomes following surgery were
those with pre and post-operative lymphopenia (HR =
2.340; 95 % CI: 1.524–3.593; p < 0.0001). Finally, we ob-
served that the existence of post-operative lymphopenia
categorizes patients into one group with poor prognosis
(HR more than 2) whatever the pre-operative lympho-
cyte count. (Table 2, Fig. 2c and d).
d’Engremont et al. BMC Cancer  (2016) 16:823 Page 5 of 12
Table 2 Univariate analysis of pre-operative, tumoral post-operative, therapeutic post operative and lymphopenia parameters for




of Deaths HR 95 % CIa P
Pre-operative parameters Age at surgery — years
≤ 65 174 130 1
> 65 216 179 1.405 [1.120; 1.764] 0.0034
Patient sex
Male 222 169 1
Female 168 140 1.224 [0.978; 1.533] 0.0769
Diabetes
No 252 199 1
Yes 73 61 1.188 [0.891; 1.584] 0.2416
Albuminemia 191 154 0.973 [0.953; 0.993] 0.0089
Tumor Size in cm 301 233 1.011 [0.931; 1.099] 0.7899
Post-operative tumoral parameters pT Local invasion
0-1-2 39 27 1
3–4 336 270 1.331 [0.895; 1.980] 0.1575
N status
0 119 89
1 269 218 1.148 [0.897; 1.470] 0.2740
Lymph Nodes ratio
< 0.2 279 205
≥ 0.2 104 96 1.759 [1.373; 2.252] <0.0001
Positive lymp nodes ratio
(N+/Total number of lymph nodes)
380 300 3.308 [1.962; 5.577] <0.0001
Histological Grade
Poorly differentiated 85 67 1
Moderately differentiated 158 127 0.797 [0.592; 1.072]
Well differentiated 88 64 0.672 [0.476; 0.947] 0.0735
Vascular invasion
No 242 179 1
Yes 119 102 1.437 [1.125; 1.836] 0.0037
Lymphatic invasion
No 230 174 1
Yes 134 110 1.199 [0.944; 1.524] 0.1374
Perineural invasion
No 138 103 1
Yes 227 183 1.172 [0.920; 1.493] 0.1989
Therapeutic post-operative parameter Adjuvant Chemotherapy— no. (%)
No 85 73 1
Yes 251 194 0.505 [0.385; 0.663] <0.0001
Lymphopenia parameters Pre-operative lymphocyte count 390 309 0.692 [0.546; 0.877] 0.0023
Post-operative lymphocyte count 301 225 0.674 [0.508; 0.895] 0.0065
Pre-operative lymphocyte count
≤ 1000 110 98 1
> 1000 280 211 0.693 [0.545; 0.881] 0.0028
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Long-term survivor patient’s description
Among the 390 patients enrolled, 67 (17 %) and 28 (7 %)
were alive at 48 and 72 months respectively (Table 4).
Lymph node ratio, venous emboli and adjuvant chemo-
therapy were identified as predictive factors for long-
term survival.
Among the 67 patients alive at 48 months, pre and
post-operative lymphocyte counts were available for 67
and 57 patients respectively. 56 (84 %) and 54 (95 %)
patients alive at 48 months had pre and post-operative
lymphocyte counts above 1000/mm3 respectively. 82
(27,2 %) patients of the overall population displayed
baseline lymphopenia. Interestingly, patients who recov-
ered an absolute lymphocyte count above 1000/mm3
1 month after surgery (n = 54) had a similar probability
to be alive at 6 years compared to the 182 patients who
were never classified as lymphopenic (6 year survival
rate of 10 % and 9.75 % respectively). Conversely, the 6-
year survival rates of patients with lymphopenia before/
after surgery or who became lymphopenic post-surgery
were respectively 0 and 2.7 %. Altogether, the analysis of
patients in long-term remission showed that 54 (22.8 %)
and 23–236 (9.75 %) with a 1-month lymphocyte count
above 1000/mm3 were alive at 4 and 6 years after sur-
gery, respectively. By contrast, the probability of sur-
vival at 4 and 6 year was only 4.6 % (n = 3) and 1.5 %
(n = 1) among patients with post-operative lymphopenia
compared to 11 (n = 9) and 6 % (n = 5) for patients with
pre-operative lymphopenia (Table 4).
Discussion
The prognostic value of lymphopenia has been previ-
ously identified in different malignancies including pan-
creatic cancers [15–19, 27]. However, these results did
not sustain the use of lymphopenia as a stratification
criterion for clinical trials or to predict overall survival.
Our study contributes to better determine the added
value of lymphopenia in localized pancreatic cancer.
Table 2 Univariate analysis of pre-operative, tumoral post-operative, therapeutic post operative and lymphopenia parameters for
association with Overall Survival (N = 390) (Continued)
Post-operative lymphocyte count
≤ 1000 65 56 1
> 1000 236 169 0.485 [0.356; 0.660] <0.0001
Pre and post-operative lymphocyte count category
> 1000/>1000 182 123 1
≤ 1000/>1000 54 46 1.486 [1.058; 2.088]
> 1000/≤1000 37 30 2.213 [1.476; 3.317]
≤ 1000/≤1000 28 26 2.340 [1.524; 3.593] <0.0001
Abbreviations: HR hazard ratio, pT histologic tumoral invasion, Nstatus lymph node status, F-up follow-up, Nratio lymph node ratio (Number of positive lymph
nodes/Total number of lymph nodes
aCI denotes confidence interval
Table 3 Multivariate final model with Pre-operative, tumoral post-operative, therapeutic post operative and lymphopenia parameters




of Deaths HR 95 % CIa P 95 % bootstrap BCA
Lymph Nodes Ratio
< 0.2 189 132 1
≥ 0.2 52 47 1.963 [1.385; 2.782] 0.0001 [1.37650; 2.70673]
Vascular invasion
No 165 117 1
Yes 76 62 1.515 [1.098; 2.089] 0.0114 [1.08206; 2.04072]
Adjuvant Chemotherapy— no. (%)
No 48 38 1
Yes 193 141 0.546 [0.377; 0.790] 0.0014 [0.34875; 0.86607]
Pre-operative lymphocyte count 241 179 0.639 [0.450; 0.909] 0.0128 [0.46779; 0.95517]
Post-operative lymphocyte count 241 179 0.731 [0.517; 1.034] 0.0764 [0.50567; 1.00832]
Abbreviations: HR hazard ratio, Lymph Nodes ratio (Number of positive lymph nodes/Total number of lymph nodes)
aCI denotes confidence interval
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Neutrophil-Lymphocyte ratio (NLR) was previously
proposed as an independent prognostic factor for over-
all survival both in localized [18–20] and in metastatic
ductal pancreatic adenocarcinoma [28]. Nevertheless,
NLR has some limitations. It includes two potentially
independent biological factors. While neutrophils are
related to inflammation, lymphocytes are directly in-
volved in immune regulation. Moreover, NLR cut off
differs from one study to another. In addition, other
biological parameters related to inflammation, such as
C-reactive protein, were shown to be significantly cor-
related to a poor clinical outcome [29].
We recorded 9 studies addressing the potential prog-
nostic impact of pre-operative lymphopenia in localized
pancreatic cancers (Additional file 5: Table S3). Only
three of them identified NLR as an independent prognos-
tic factor in multivariate analysis [18, 19, 30]. Our study
confirms with statistical robustness that pre-operative
lymphocyte count is an independent prognostic factor in
pancreatic cancer on a larger scale (Table 3 and Fig. 2a;
HR of 0,64; 95 % CI 0.450–0.909; p = 0.0013). The median
of lymphocyte count in our cohort is in line with those
observed previously in the studies of Garcea et al., and
Stotz et al. [18, 31].
Having observed that 66 % of the patients in the
pre-operative lymphopenia group had a total lympho-
cyte count above 1000/mm3 1 month after surgery,
the prognostic value of post-operative lymphopenia
was also investigated and demonstrated. (Table 3 and
Fig. 2b; HR of 0.731 (95 % CI: 0.52–1.034; p = 0.076).
The statistical significance of the postoperative lym-
phopenia is supported by the good discrimination of
the final model (Additional file 3: Figure S2, C-statistic
0.64; 95 % CI: 0.60–0.69), as well as the calibration
analyses (bootstrap mean difference of 0.04; 95 % CI,
0.01–0.06).
Fig. 1 Additive value of the pre and post-operative lymphocyte count information for the reclassification of risk of death (continuous NRI) at
48 months after the diagnosis. Blue lines in patients without death indicate that pre and post-operative lymphocyte count information moved risk
prediction in the correct (downward) direction (47/81 = 58 %). Conversely, red lines in patients with death indicate a correct, upward, change in
risk assessment when using the pre and post-operative lymphocyte count information (94/160 = 59 %)
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Romano et al., have shown that post-operative immu-
nodepression was significantly higher in pancreatic can-
cers than in colorectal and gastric cancers. Interestingly,
recovery of normal post-operative lymphocyte count was
longer in pancreatic cancers [32]. Only one small-scale
study reported a negative relation between post-operative
day 1 lymphopenia and overall survival for 111 patients
with pancreatic cancer (p = 0.0029) [33]. However, most of
the patients recovered from their decreased lymphocyte
count several days following surgery and we postulated
that lymphopenia monitored 1-month after the surgery
might be more relevant to explore its influence on long
term survival.
Of note, there are some limitations in our study. First,
there are some differences between the two cohorts.
Despite these differences the survival prognosis of the
patients in the two cohorts was not significantly different
(Additional file 1: Figure S1, Log-rank p value = 0.2236).
From a statistical point of view, the assessment of model
performance measures such as discrimination, calibration
and internal validation strengthen the present investigation.
Addition of lymphocyte count variable to the conven-
tional parameter block, in multivariate analysis, signifi-
cantly improved the model discrimination capacity
because the C statistic increased significantly from 0.60
to 0.64 (bootstrap mean difference = 0.04; 95 % CI,
0.01–0.06) demonstrating the additive value of lympho-
penia to other conventional parameters. The use of a
threshold offered better discrimination than the use of
lymphocyte count because it allows death-risk stratifica-
tion. In addition, combining the categorical (≤1000; >1000)
information in pre and post-operative lymphocyte
counts permitted the identification of several subgroups
of patients with different prognoses. Patients with the
worse prognosis were those with pre and post-operative
lymphopenia (HR = 2.340; 95 % CI: 1.524–3.593; p <
0.0001). Patients who displayed lymphopenia prior to
surgery and recovered absolute lymphocyte count
above 1000/mm3 1 month following pancreatic cancer
removal had a better prognostic than patients without
correction of lymphopenia (p < 0.0001). Consequently,
the measure of lymphopenia seems more discriminant
A B
C D
Fig. 2 Kaplan-Meier curves for patient’s survival according to pre-operative lymphocyte count value (Panel a), to post-operative lymphocyte count
value (Panel b) and to combination of the categorical (>1000; ≤1000) information in post and pre lymphocyte counts (Panel c). Panel d represent
Hazard ratio for death-risk according to post and pre lymphocyte counts
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in the post-operative setting and has improved additive
value for death risk stratification.
Finally, the analysis of long-term survival patients
showed that 23 of the 24 patients alive 6 years after the
surgery had 1-month lymphocyte count above 1000/mm3.
These results suggest that lymphopenia is one of the
most important prognostic factors to predict long term
overall survival. The impact of lymphopenia on long-
term survival was also reported in metastatic patients.
Indeed, a recent study including patients treated with
nabpaclitaxel and gemcitabine or with gemcitabine alone
reported that the number of patients alive at least
24 months after treatment initiation was increased if
NLR was below 5 [28]. Such results support the inclu-
sion of lymphopenia as a risk stratification criterion in
clinical trials and in models to determine the probability
of overall survival.
Prospective immunological monitoring of those patients
is needed to better explain the precise mechanisms in-
volved in lymphocyte homeostasis in pancreatic cancer
patients. The role of the immune system was pointed out
by studies investigating the influence of TIL on pancreatic
cancer prognosis. The frequency of CD8+ T lymphocytes
was correlated to favourable clinical outcomes and
prolonged survival [34–36]. The polarization of CD4+ T
lymphocytes is another possible relevant immunological
parameter correlated to patients’ survival in several can-
cers [37]. GATA3/Tbet ratio and TH2 infiltrates were pro-
posed as an independent prognostic factor for pancreatic
cancer patients treated by surgery [38]. In this study, a
predominant TH2 infiltrate was observed in peritumoral
stroma suggesting a skewing of local immune responses
toward TH2 polarization [38, 39]. Moreover, regulatory T
cell infiltration in pancreatic cancer tissue increases during
disease progression and was evidenced as a prognostic fac-
tor in resected pancreatic cancers [40]. On the other hand,
lymphopenia might reflect a global metabolism alteration
such as malnutrition [41]. Albuminemia was monitored in
191 out of the 390 (49 %) patients included in our cohort.
We observed an influence of hypoalbuminemia on OS in
univariate analysis (HR = 0.97, p = 0.009). Albuminemia
was initially droped out of multivariate analysis due to
Table 4 Description of the parameters of interest in the Overall population and in the long-term survivor population (>48 months
and >72 months)
Patients Characteristics Overall population
(N =390)
Long-term survivor
(>48 months) (N =67)
Long-term survivor
(>72 months) (N =28)
N N N
Conventional parameters Lymph Nodes ratio 380 67 28
< 0.2 279 (73 %) 59 (88 %) 27 (96 %)
≥ 0.2 104 (27 %) 8 (12 %) 1 (4 %)
Vascular invasion 361 65 28
No 242 (67 %) 51 (78 %) 23 (82 %)
Yes 119 (33 %) 14 (22 %) 5 (18 %)
Adjuvant Chemotherapy— no. (%) 336 58 22
No 85 (25 %) 6 (10 %) 3 (14 %)
Yes 251 (75 %) 52 (90 %) 19 (86 %)
Lymphopenia parameters Pre-operative lymphocyte count 390 1320 (150–8350) 67 1330 (390–3360) 28 1350 (560–2970)
Post-operative lymphocyte count 301 1410 (200–32000) 57 1600 (930–3620) 24 1589 (940–2976)
Pre-operative lymphocyte count 390 67 28
≤ 1000 110 (28 %) 11 (16 %) 6 (21 %)
> 1000 280 (72 %) 56 (84 %) 22 (79 %)
Post-operative lymphocyte count 299 57 24
≤ 1000 65 (22 %) 3 (5 %) 1 (4 %)
> 1000 236 (78 %) 54 (95 %) 23 (96 %)
Lymphocyte count pre and post combined 301 57 24
> 1000/>1000 182 (60 %) 46 (81 %) 18 (75 %)
≤ 1000/>1000 54 (18 %) 8 (14 %) 5 (21 %)
> 1000/≤1000 37 (12 %) 2 (4 %) 1 (4 %)
≤ 1000/≤1000 28 (10 %) 1 (2 %) 0 (0 %)
Abbreviations: Lymph Nodes Ratio (Number of positive lymph nodes/Total number of lymph nodes)
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it’s high rate of missing data. When performing the
multivariate analysis with albuminemia (n = 152) similar
results were obtained for veinous emboli and chemother-
apy parameter (p = 0.0035 and p = 0.0010, respectively),
even if the low number of data prompted further investi-
gations to conclude.
However, the direct role of albuminemia as an inde-
pendent prognostic factor remained unclarified, as this
parameter is mostly not significant in multivariate analysis
[6]. The hypothesis of a direct influence of the tumour on
lymphocyte homeostasis is plausible and supported by
the capacity of the tumour to secret immunosuppressive
cytokines like IL-10 and TGFβ [37]. Another possible
hypothesis might be the production of lymphocyte-
apoptosis inducers such as Fas-Ligand, by pancreatic
ductal adenocarcinoma [42].
One-month post-operative lymphopenia has inde-
pendent and additive values for death risk stratification
in localized pancreatic adenocarcinoma. The clinical
significance of lymphopenia after surgery is highlighted
by its negative correlation with the probability of long-
term survival. The development of strategies based on
immunonutrition [43], recombinant IL-7 [44], to ex-
pand CD4 T cells and the preliminary results of novel
immunotherapies [45], offer new therapeutic endpoints
to be assessed in pancreatic cancer patients.
Conclusions
Our study demonstrated the additive value of post-
operative lymphopenia to stratify pancreatic cancer pa-
tients' risk of death. Post-operative lymphopenia is an in-
dependent predictive factor of long term survival.
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